Cited by 1,192Diabetes Treatment and ManagementDiabetes Management and ResearchHeart Failure Treatment and Management

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Open access

Buse, John B., Wexler, Deborah J., Tsapas, Apostolos, Rossing, Peter, Mingrone, Geltrude, Mathieu, Chantal, D’Alessio, David A., Davies, Melanie J.·2020·Diabetes Care

DOI 10.2337/dci19-0066PMC PMC6971782

Open this paper in CoChat — free account Open PDF

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min–1 [1.73 m]–2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/dci19-0066

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citation
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“Somemeta-analyses (5,13,14) suggest the presence of heterogeneity in estimates forMACE andCVdeathwithGLP-1 receptor agonists, although this ismostly due to the results of a single trial with lixisenatide.”
Result
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Self-citation
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084

Flagged first, then by citations

Show all 21 references

Sorted by citations

Items 801–900 of 1,000

Study on Influencing Factors of Radial Artery Occlusion after Repeated Right Radial Artery Coronary Intervention
Wang, J., Yi, C., & Jianming, Z. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/9624339 · Cited by 3
GLP-1 Receptor Agonists Critical Review: Revisiting Its Positioning for Type 2 Diabetes Mellitus in Routine Clinical Practice in India
Rajput, R., Sinha, B., Lodha, S., Deb, P., Das, S., Agarwal, S., Das, A. K., & Thomas, N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0026 · Cited by 4
Mode of treatments and achievement of treatment targets among type 2 diabetes patients with different comorbidities – a register-based retrospective cohort study in Finland
Nazu, N. A., Wikström, K., Lamidi, M., Lindström, J., Tirkkonen, H., Rautiainen, P., & Laatikainen, T. K. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01889-3 · Cited by 3
Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand
Deerochanawong, C., Krittayaphong, R., Romano, J. G. U., Rhee, N. A., & Permsuwan, U. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01371-y · Cited by 5
Revolutionizing diabetes care: unveiling tirzepatide’s potential in glycemic control and beyond
Sood, A., Kaur, P., Syed, O., Sood, A., Aronow, W. S., Borokhovsky, B., Bhatia, V., & Gupta, R. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2310070 · Cited by 3
Evidence-based prescribing of diabetes medications: are we getting closer?
Bellary, S., Tahrani, A. A., & Barnett, A. H. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30020-6 · Cited by 3
Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Ding, L., Sun, B., Xiao, X., & Kin, T. (2020) · International Journal of Endocrinology · doi:10.1155/2020/1626484 · Cited by 3
Diabetes and the Heart: New Clinical Trials and Recent Recommendations
Paschou, S. Α., & Siasos, G. (2020) · Current Pharmaceutical Design · doi:10.2174/138161282637200925102942 · Cited by 3
The Administration of Xultophy for Diabetic Patients on Hemodialysis
Fujikawa, T., Kato, Y., Bando, H., Kakutani, H., Kawata, T., Yamamoto, M., Wada, K., Ishikura, K., Shirai, Y., Narutaki, M., et al. (2020) · doi:10.36502/2020/droa.6172 · Cited by 3
Metabolic and sympathovagal effects of bolus insulin glulisine versus basal insulin glargine therapy in people with type 2 diabetes: A randomized controlled study
Takeshita, Y., Tanaka, T., Wakakuri, H., Kita, Y., Kanamori, T., & Takamura, T. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13471 · Cited by 3
KDIGO-Leitlinie zur Behandlung des Diabetes mellitus bei chronischer Nierenerkrankung
Busch, M., Mann, J. F. E., & Wolf, G. (2021) · Der Nephrologe · doi:10.1007/s11560-021-00498-y · Cited by 3
Advances in Exercise and Nutrition as Therapy in Diabetes
Riddell, M. C., Davis, E. A., Mayer‐Davis, E. J., Kahkoska, A. R., & Zaharieva, D. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.2509 · Cited by 3
Identification of the Inappropriate Clinical Actions (DON'T) to Improve the Management of Patients with Type 2 Diabetes Failing Basal Insulin Supported Oral Treatment: Results of Survey for a Panel of Diabetes Specialists in Italy
Leto, G., Barchetta, I., Candia, L. D., Magotti, M. G., Cianciullo, M., Manti, R., Negri, C., Cimino, V., Dodesini, A. R., Zerella, F., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01137-4 · Cited by 3
Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials
Kanasaki, K., Qu, S., Yamamoto, F., Schepers, C., Simões, R. S., Yabe, D., & Ji, L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.1999409 · Cited by 3
Use of dipeptidyl peptidase‐4 inhibitors and risk of splanchnic vein thrombosis: A Danish nationwide new‐user active comparator cohort study
Pottegård, A., Lund, L. C., Henriksen, D. P., Folkestad, L., Hellfritzsch, M., Hallas, J., & Kristensen, K. B. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14253 · Cited by 3
Real-world barriers and safety of initiating sodium-glucose co-transporter 2 inhibitor treatment immediately following an acute cardiac event in people with diabetes
Hitchen, S. A., Lan, N. S. R., Rankin, J. M., Larbalestier, R. I., Yeap, B. B., & Fegan, P. G. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108057 · Cited by 3
Heterogeneity of Diabetes: β-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Research’s Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases
Cefalu, W. T., Andersen, D. K., Arreaza-Rubín, G., Pin, C. L., Sato, S. M., Verchere, C. B., Woo, M., Rosenblum, N. D., Rosenblum, N. D., Cefalu, W. T., et al. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.09.126 · Cited by 3
Komplementer és additív hatások – a GLP-1-receptoragonisták és az SGLT-2-gátlók kardiorenális előnyeinek patobiokémiai háttere
Winkler, G. (2021) · Diabetologia Hungarica · doi:10.24121/dh.2021.17 · Cited by 3
Diabetes and Kidney disease: metformin
Gnudi, L., & Ricciardi, C. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_24 · Cited by 3
A case of metformin-associated lactic acidosis with cardiogenic and vasoplegic shock supported by ECPella
Ling, S. K.-H., Chung, K. W., & Yee, H. (2023) · Perfusion · doi:10.1177/02676591231181851 · Cited by 3
Reducing cardiovascular risk in type 2 diabetes: Let's use all we have!
Bonaventura, A. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.04.014 · Cited by 3
Positioning newer drugs in the management of type 2 diabetes
Marx, N., Davies, M. J., Grant, P. J., Mathieu, C., Petrie, J. R., Cosentino, F., & Buse, J. B. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00021-8 · Cited by 3
Self-citation
Patterns of Medication Use and Prescription Fills for Cardioprotective Anti-Hyperglycemic Agents in the United StatesPreprint
Nargesi, A. A., Clark, C. N., Chen, L., Liu, M., Reddy, A., Amodeo, S., Oikonomou, E. K., Suchard, M. A., McGuire, D. K., Lin, Z., et al. (2022) · medRxiv · doi:10.1101/2022.01.31.22270187 · Cited by 3
Metformin
and, J. T., & Boyle, J. (2022) · doi:10.1002/9781119785033.ch2 · Cited by 3
Diabetic Nephropathy
Rossing, P. R., & Flyvbjerg, A. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch44 · Cited by 3
Self-citation
Role of Therapeutic Potential, Contemporary Management, Unmet needs of SGLT2 Inhibitors in Congestive Heart Failure
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_6 · Cited by 3
Risk of Incident Cancer in Veterans with Diabetes Who Use Metformin Versus Sulfonylureas
Abdallah, M. M., de Oliveira, B. D., DuMontier, C., Orkaby, A. R., Nussbaum, L. S., Gaziano, J. M., Djoussé, L., GAGNON, D. R., Cho, K., Preis, S. R., et al. (2024) · Journal of Cancer Prevention · doi:10.15430/jcp.24.012 · Cited by 3
The association of KEAP1 and NFE2L2 polymorphisms with glycemic control and late complications in patients with type 2 diabetes
Vraničar, Z., Goričar, K., Blagus, T., Dolžan, V., & Klen, J. (2025) · Gene · doi:10.1016/j.gene.2025.149631 · Cited by 2
Prebiotic dietary fibre from marine seaweed: A potential treatment strategy for type 2 diabetes
Gopal, R. K., Ganesh, P. S., & Pathoor, N. N. (2025) · Algal Research · doi:10.1016/j.algal.2025.104368 · Cited by 2
Morinda citrifolia L. (noni) and its potential in the management of systemic metabolic disorder (SMD)
Li, C.-H., Huang, Y.-X., Duan, Y., Liu, G.-P., Ai, Z.-W., Ai, Z.-F., Li, J., & Li, S. (2025) · Food & Function · doi:10.1039/d5fo03892h · Cited by 2
Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort study
Güdemann, L. M., Young, K., Cardoso, P., Mateen, B. A., Holman, R. R., Sattar, N. A., Pearson, E. R., Hattersley, A. T., Jones, A. G., Shields, B. M., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101547 · Cited by 2
Advancing Cardiorenal Interaction: From Pathophysiological Paradigms to Novel Therapeutic Strategies
Wei, L., He, P., Gao, J., Huang, L., Zhao, L., Zhang, R., Ning, X., & Sun, S. (2025) · Kidney Diseases · doi:10.1159/000548367 · Cited by 2
Real‐World Evidence on Mobile App–Supported Diabetes Management in Insulin‐Treated Patients
Roth, L., Stein, J., & Schwarz, P. E. H. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/6671361 · Cited by 2
GLP-1 receptor agonist–SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes
Mao, X., Fan, H., Yuen, M.-F., Cheung, R. C., Seto, W., & Nguyen, M. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001771 · Cited by 3
Putative functional non-coding polymorphisms in SELP significantly modulate sP-selectin levels, arterial stiffness and type 2 diabetes mellitus susceptibility
Kaur, R., Singh, J., Kapoor, R., & Kaur, M. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00548-x · Cited by 2
Update Typ-2-Diabetes
Hamann, A. (2020) · Die Diabetologie · doi:10.1007/s11428-020-00627-6 · Cited by 2
Signal Peptide Optimization to Prevent N-terminal Truncation of Glucagon Like Peptide-1/IgG-Fc Fusion Protein
Cao, C., Wei, S., Xu, X., Song, S., Lai, Y., & Li, J. (2020) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-020-10112-9 · Cited by 2
Exploring early combination strategy in Latin American patients with newly diagnosed type 2 diabetes: a sub-analysis of the VERIFY study
Vencio, S. A. C., Manosalva, J. P., Mathieu, C., Proot, P., Yupanqui-Lozno, H., & Paldánius, P. M. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00686-9 · Cited by 2
Self-citation
Effect of ipragliflozin on metabolic syndrome components and non-alcoholic fatty liver disease
Petunina, N. A., Эдуардовна, Т. М., & Кузина, И. А. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-12-305-310 · Cited by 2
Compliance with Prescription Guidelines for Glucose-Lowering Therapies According to Renal Function: Real-Life Study in Inpatients of Internal Medicine, Endocrinology and Cardiology Units
Lohan, L., Galtier, F., Manson, T., Mura, T., Castet‐Nicolas, A., Faure, D., Chapet, N., Leclercq, F., Pasquié, J., Roubille, F., et al. (2021) · Medicina · doi:10.3390/medicina57121376 · Cited by 2
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease
Karalliedde, J. J., Winocour, P. H., Chowdhury, T. A., De, P., Frankel, A., Montero, R., Pokrajac, A., Banerjee, D., Dasgupta, I., Fogarty, D. G., et al. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2021.328 · Cited by 2
Type 2 diabetes pharmacotherapy trends in high‐risk subgroups
Bae, J. P., Liu, D., Chinthammit, C., KADZIOLA, Z. A., Boye, K. S., & Mather, K. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14678 · Cited by 3
Cardiovascular and renal outcomes of initial combination therapy with glucose‐lowering agents versus a stepwise approach in newly diagnosed or treatment‐naïve type 2 diabetes: A systematic review and meta‐analysis
Seidu, S., Almaqhawi, A., Abdool, M., Kunutsor, S. K., Davies, M. J., & Khunti, K. K. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14715 · Cited by 2
Self-citation
Precision Medicine in Diabetes
Dawed, A. Y., Haider, E., & Pearson, E. R. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_590 · Cited by 5
Executive summary on the treatment of type 2 diabetes mellitus in elderly or frail individuals. 2022 update of the 2018 consensus document “Treatment of type 2 diabetes mellitus in the elderly”
Peralta, F. G., Carrasco-Sánchez, F. J., Pérez, A., Escalada, J., Guisasola, F. Á., Fernández-Santos, C. M., Bravo, J. J. M., & Gómez‐Huelgas, R. (2022) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2022.03.005 · Cited by 2
Efficacy and safety of oral semaglutide in Russian patients with type 2 diabetes: subgroup analysis of PIONEER 1, 2, 3 trials
Шамхалова, М. Ш., & Shestakova, M. V. (2022) · Diabetes Mellitus · doi:10.14341/dm12941 · Cited by 3
The diagnostic model for early detection of gestational diabetes mellitus and gestational diabetic nephropathy
Chong, H., Li, J., Chen, C., Wang, W., Liao, D., & Zhang, K. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24627 · Cited by 2
Refractory arterial hypertension: hyperactivity of the sympathetic nervous system, kidney and approaches to antihypertensive drug therapy
Ob, K., Викторович, Ж. В., Викторовна, Б. Н., & Landar, L. N. (2022) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2022-28-5-600-608 · Cited by 2
CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece
Ghetti, G., Pradelli, L., Papageorgiou, G., Karpouzos, G., & Arikan, Y. (2023) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s400522 · Cited by 2
Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis
Yao, J., Zhang, M., Zhang, X., & Zhang, J. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01369-6 · Cited by 2
Pharmacogenomics and diabetes
Naz, F., Qadir, R., Baammi, S., Ali, A., & Rehman, M. U. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15336-5.00012-9 · Cited by 2
Preoperative Patient Evaluation
Villasenor, M., & Selzer, A. R. (2023) · Anesthesiology Clinics · doi:10.1016/j.anclin.2023.08.004 · Cited by 2
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy
Ren, H., Berry, S., Malkin, S. J. P., Hunt, B., & Bain, S. C. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-070473 · Cited by 4
Predicting marital adjustment of wives through emotional intelligence, health literacy, and perceived stress of diabetic husbands: mediating role of sexual satisfaction
Birkan, R. R., & Bakhtiarpour, S. (2024) · Current Psychology · doi:10.1007/s12144-023-05600-2 · Cited by 2
Antidiabetic efficacy of sea fish oil in ameliorating hyperglycaemia by enhancing FFAR1, GLP-1 and inhibiting DPP-4 signalling in the pancreatic tissues of high lipid diet and streptozotocin-induced type 2 diabetic rats
Pyne, S., Mandal, M., Das, S. K., Bhowmick, S., Das, K., Rao, J. S., & Laha, J. (2023) · Acta Biologica Szegediensis · doi:10.14232/abs.2023.1.87-101 · Cited by 2
LADA 30th anniversary: A growing form of diabetes with persistent unresolved questions
Jia, I. L. J., Buzzetti, R., Leslie, R. D., & Pozzilli, P. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3800 · Cited by 2
Comparing the accuracy of four machine learning models in predicting type 2 diabetes onset within the Chinese population: a retrospective study
Liu, H., Dong, S., Yang, H. S., Wang, L., Liu, J., Du, Y., Liu, J., Lyu, Z., Wang, Y., Jiang, L., et al. (2024) · Journal of International Medical Research · doi:10.1177/03000605241253786 · Cited by 3
Efficacy of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort
Lu, D., Zheng, R., Li, A., & Zhang, J. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.98552 · Cited by 2
Correlation of inflammatory markers and NFATC4 gene expression among subjects with prediabetes
Rajan, A., Lakshmanan, K., Vidya, S., Sheena, K. S., Harilal, M. D., Deepthi, S., Manjusha, K., Raveendran, R. R. R., Ambili., P., Midhun, T., et al. (2024) · Journal of Cardiovascular and Thoracic Research · doi:10.34172/jcvtr.33272 · Cited by 2
Recommended procedures for diabetic kidney disease 2021
Pelikánová, T., Viklický, O., Rychlík, I., Saudek, F., Tesař, V., Haluzı́k, M., Kvapil, M., Racek, J., & Zima, T. (2021) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2021.016 · Cited by 2
DPP-4-gátlók a 2-es típusú diabetes kezelésében – megújult irányelvek, változó klinikai gyakorlat
Jermendy, G., Gaál, Z., Kempler, P., Lengyel, C., Rosta, L., Várkonyi, T. T., & Wittmann, I. (2020) · Diabetologia Hungarica · doi:10.24121/dh.2020.6 · Cited by 2
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
Bernfort, L., Husberg, M., Wiréhn, A.-B., Rosenqvist, U., Gustavsson, S., Karlsdotter, K., & Levin, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00937-4 · Cited by 2
GLP1-receptor-agonisták: antidiabetikumok kardiovaszkuláris előnnyel
Jermendy, G. (2020) · Cardiologia Hungarica · doi:10.26430/chungarica.2020.50.4.283 · Cited by 2
The 80th annual (virtual) conference of the American Diabetes Association: June 12–16, 2020
Suliman, M., Mohammed, N., & Suliman, S. (2020) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.4103/ijmbs.ijmbs_106_20 · Cited by 2
Herzinsuffizienz bei Menschen mit Diabetes mellitus
Schütt, K. A. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00752-w · Cited by 2
A Multifactorial Approach in Type 2 Diabetes Over 3 Years Decelerates Progression of Subclinical Arterial Disease in Routine Clinical Practice
Konstantonis, G. D., Arida, A., Aissopou, E. K., Protogerou, A. D., Tentolouris, N., Sfikakis, P. P., & Makrilakis, K. (2021) · Angiology · doi:10.1177/00033197211010622 · Cited by 2
Fast-acting insulin aspart - from insulin portraits to patient portraits
Demidova, T. Y., & Izmaylova, M. Y. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-7-8-16 · Cited by 2
Cross sectional study on proportion of sulfonylureas among various oral antidiabetic drugs using for Japanese patients with type 2 diabetes, analyzed from NSAID Study-2
Arai, K., Nishikawa, T., Shirabe, S., Matsuzawa, Y., Ohtsu, S., Yuasa, S., Hirao, K., & Mori, H. (2021) · Diabetology International · doi:10.1007/s13340-021-00520-7 · Cited by 2
Association of serum cardiac troponin I and severity of coronary stenosis in patients with varied renal functions: a retrospective cohort study
Zhang, Q., Wang, Y., Hu, X., Tan, Y., Gao, C., Chen, J., Han, F., Chen, J., & Yang, Y. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054722 · Cited by 2
Association of Inflammatory Markers with Multisite Artery Disease in Patients with Peripheral Arterial Disease
Yalım, Z., Aldemir, M., & Emren, S. V. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.04.001 · Cited by 2
Usefulness of circulating EPAC1 as biomarkers of therapeutic response to GLP-1 receptor agonists
Hernández, C., Peralta, F. G., Simó‐Servat, O., García‐Ramírez, M., Abreu, C., Rodríguez, S. G., & Simó, R. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01928-6 · Cited by 2
Impact of breakthrough trials on prescription trends of sodium‐glucose cotransporter‐2 inhibitors in Japan: An interrupted time‐series analysis
Iketani, R., & Imai, S. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13768 · Cited by 2
Hand grip strength: A reliable assessment tool of frailty status on the person with type 2 diabetes mellitus
Ramalho, D., Silva, M. L., Almeida, C., Rocha, L., Rocha, G., & Veríssimo, R. (2023) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2022.10.004 · Cited by 2
Treatment of Patients Chronic Coronary Heart Disease and Type 2 Diabetes Mellitus
Shchukina, E. V. S., Приколота, О. А., Bagriy, V. A., Андрусяк, А. Ю., Gs, R., Shesterina, Y. B., & Stefano, E. (2023) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2023-13-2-97-109 · Cited by 2
Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948–1957
Singh, A. K., Singh, R., & Khunti, K. K. (2020) · Diabetes Care · doi:10.2337/dc20-1950 · Cited by 2
Priorities and practicalities of prescribing diabetes medicines with cardiovascular and renal protective effects: an Australian perspective
Hitchen, S. A., Lan, N. S. R., Fegan, P. G., & Yeap, B. B. (2020) · Internal Medicine Journal · doi:10.1111/imj.15055 · Cited by 2
FULMINANT MYOCARDITIS-A UNIQUE COMPLICATION OF COVID-19
Ahmed, A., Young, S. K., & Lantz, R. H. (2021) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(21)03378-7 · Cited by 2
The Role of Diabetes Mellitus in the Malignant Pancreatic Cyst Neoplasm Diagnosis and Prognosis
Deng, J., Guo, Y., Gu, J., Du, J., Kong, L., Tao, B., Li, J., & Fu, D. (2022) · Cancer Management and Research · doi:10.2147/cmar.s355365 · Cited by 2
Comment on Samara et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020;43:2691–2701
Violante-Cumpa, J. R., Pérez-Arredondo, L. A., González‐González, J. G., & Mancillas‐Adame, L. G. (2021) · Diabetes Care · doi:10.2337/dc20-2881 · Cited by 2
Increased serum total bile acid is independently associated with non-alcoholic steatohepatitis in non-diabetes populationPreprint
Li, H., Ma, J., Gu, L., Jin, L., Chen, P., Zhang, X., & Chen, L. (2020) · doi:10.21203/rs.3.rs-27123/v1 · Cited by 2
Diabetes mellitus: what the neurologists need to know
Stephens, J. W., Williams, D. M., & Chudleigh, R. A. (2022) · Practical Neurology · doi:10.1136/pn-2022-003395 · Cited by 2
Antidiabetic drugs and hypoglycaemia risk in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants
Nabrdalik, K., Kwiendacz, H., & Lip, G. Y. H. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad042 · Cited by 2
Cerebrovascular Disease and Diabetes
Amory, C. F., Weinberger, J. M., & Smith, T. S. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch51 · Cited by 2
Care of Diabetes and the Sacrifice of Evidence-Based Medicine and Health Equity
Goldberg, D. N. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08907-3 · Cited by 2
An overview of the once‐weekly GLP‐1 receptor agonists from the pharmacist’s perspective
Patel, D. K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13227 · Cited by 1
The Role of Physicians’ Digital Tools in Pharmacological Management of Type 2 Diabetes Mellitus
Janež, A., Ješe, R., Haluzík, M., & Rizzo, M. (2022) · Medicina · doi:10.3390/medicina58081061 · Cited by 1
Personalized Medicine Literacy
Geantă, M., Боата, А., Brand, A. M., Cioroboiu, C., & Cucoş, B. (2022) · Springer eBooks · doi:10.1007/978-981-19-5082-7_12 · Cited by 1
Dietary inclusion of coconut and date palm fruit blend attenuate hyperglycemia, insulin insensitivity and diabetes-induced complications in vivo
Mohammed, A., & Liman, M. L. (2023) · Food and Humanity · doi:10.1016/j.foohum.2023.10.002 · Cited by 1
Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus
Ken-Opurum, J., Srinivas, S. S. S., Jain, D., Shah, T., Samnaliev, M., DEX, T. A., Charland, S. L., Revel, A., & Preblick, R. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01477-3 · Cited by 1
KIỂM SOÁT ĐƯỜNG HUYẾT TRÊN NGƯỜI BỆNH ĐÁI THÁO ĐƯỜNG TYPE 2 ĐIỀU TRỊ NGOẠI TRÚ TẠI BỆNH VIỆN NHÂN DÂN GIA ĐỊNH
Đinh, Q. B., & Nguyễn, V. S. (2024) · Tạp chí Y học Việt Nam · doi:10.51298/vmj.v534i2.8190 · Cited by 1
Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine
Simonson, D. C., Testa, M. A., Ekholm, E., Su, M., Vilsbøll, T., Jabbour, S. A., & Lind, M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae105 · Cited by 2
Diversity of uropathogens and their antibiotic resistance among diabetic patients presented to MTI-Lady Reading Hospital, Peshawar
Masood, A., Bilal, M., Badshah, S., & Khan, Y. (2024) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.40.5.8275 · Cited by 1
Glucocorticoid does not improve the renal prognosis of patients with diabetic nephropathy combined with acute tubulointerstitial nephritis: a retrospective analysis
Tian, J., Shi, J., Jiao, Y., Liu, X., An, J., Yang, Y., Zou, G., & Zhuo, L. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2379002 · Cited by 1
Tolerability of Sodium-Glucose Co-transporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Retrospective Cohort Study
Radi, S., Almutairi, M., Alghamdi, A. S., Alzahrani, M., Alghamdi, S., Almalky, N. A., Alharbi, B., Altuwaylie, T. M., Marwani, F. A., & Saber, W. (2024) · Cureus · doi:10.7759/cureus.75798 · Cited by 1
SGLT-2 Inhibitors: The Magic Bullet for Cardio-Renal Protection in Type 2 DM
Patel, R., & Oroszi, T. L. (2024) · Pharmacology & Pharmacy · doi:10.4236/pp.2024.1512027 · Cited by 1
GLP-1 receptor agonism in cardiovascular disease prevention
Saleh, H. (2025) · Asia-Pacific Journal of Pharmacotherapy & Toxicology · doi:10.32948/ajpt.2024.11.22 · Cited by 1
Novel Ag(I) and Zn(II) complexes based on benzenesulfonamide ligand: Synthesis, characterization, and biological evaluation as multitarget antidiabetic agents
Ayoup, M. S., Yasser, M., Soliman, S. M., Abdel‐Hamid, H., Cordes, D. B., McKay, A. P., Ghareeb, D. A., Elghamry, I., Ashraf, S., Sonousi, A. S. M., et al. (2025) · Inorganica Chimica Acta · doi:10.1016/j.ica.2025.122639 · Cited by 1
Fotagliptin add‐on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double‐blind, placebo‐controlled, phase 3 trial
Yu, N., Xu, W., Guo, X., Xu, M., Zhang, W., Yan, C., Pang, S., Shu, X., Zhang, W., Peng, W., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16427 · Cited by 1
Effects of Glucagon like Peptide-1 agonists on patients with overactive bladder: A pilot study
Sandler, M. D., Williams, A. D., Wein, A., Amin, K. A., & Syan, R. (2025) · Continence Reports · doi:10.1016/j.contre.2025.100083 · Cited by 1
Social support groups and policy recommendations for managing type 2 diabetes: perspective of healthcare professionals in Ghana
Ahiale, C., & Kumah, A. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1604828 · Cited by 2

Authors: Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J.
Affiliations: University of North Carolina at Chapel Hill (US)
Harvard University (US)
Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
University of Copenhagen (DK)
Università Cattolica del Sacro Cuore (IT)
Universitair Ziekenhuis Leuven (BE)
Duke University (US)
University of Leicester (GB)
Corresponding author: Davies, Melanie J.
ORCID: Buse, John B.
Wexler, Deborah J.
Tsapas, Apostolos
Rossing, Peter
Mingrone, Geltrude
Mathieu, Chantal
D’Alessio, David A.
Davies, Melanie J.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2019-12-19
Volume: 43
Issue: 2
Pages: 487-493
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dci19-0066
PMC: PMC6971782
OpenAlex: W4253996779
Cited by: 1,192
References: 21
Citations by year: 2026: 54 · 2025: 79 · 2024: 128 · 2023: 162 · 2022: 277 · 2021: 279 · 2020: 212
FWCI: 155.76
Type: journal article
Language: en
Update notices: correction (2020-07-01)
Open access: bronze
doi.org
Licence: www.diabetesjournals.org/content/license (vor, 32 d)
Locations: Diabetes Care (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
Lirias (submittedVersion)
PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
Funders: American Diabetes Association
European Association for the Study of Diabetes
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords: hyperglycemia management, type 2 diabetes, GLP-1 receptor agonists, SGLT2 inhibitors, major adverse cardiovascular events, heart failure hospitalization, heart failure with reduced ejection fraction, chronic kidney disease progression, HbA1c targets, cardiovascular risk stratification

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks